Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Shenzhen Quadrivalent Influenza Vaccine
NCT04210349Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jan 2020
- Primary completion
- Dec 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Shenzhen Quadrivalent Inactivated Influenza Vaccine in influenza, sponsored by Sanofi. Started Jan 2020; status: completed.
02
Drugs
Shenzhen Quadrivalent Inactivated Influenza Vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT04210349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04210349.